written on 02.05.2014

Vertex, once king of hep C category, bows out as new drugs eclipse Incivek


Biotech Vertex has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences redefined the category with Sovaldi, a drug now expected to become the top seller of all time.